Falk Gastro Review Journal

Current science, compiled for you from the multitude of scientific publication and briefly summarized - that is the Falk Gastro Review Journal.

Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

The latest issues

Edition 4/2023

Edition 3/2023

Edition 2/2023

Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

All articles

Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: A multicenter, open-label, randomized controlled trial

Lancet Gastroenterol Hepatol. 2023;8(3):228–41

Rates of antimicrobial resistance in Helicobacter pylori isolates from clinical trial patients across the US and Europe

Am J Gastroenterol. 2023;118(2):269–75

Long-term outcomes of peroral endoscopic myotomy for achalasia: A systematic review and meta-analysis

Endoscopy. 2023;55(2):167–75

Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: A randomized trial

Gastroenterology. 2023;164(1):61–71

Eosinophilic gastritis and enteritis are increased in families with eosinophilic esophagitis

Am J Gastroenterol. 2023;118(2):263–8

Phase 2 trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis

Gut. 2023;72(2):256–63

Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: A prospective 16-year longitudinal cohort study

Lancet Oncol. 2023;24(1):107–16

Prevalence and prognostic significance of vitamin C deficiency in patients with acute upper gastrointestinal bleeding: A prospective cohort study

Aliment Pharmacol Ther. 2023;57(3):313–22

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): A multicenter, open-label, randomized controlled trial

Lancet Gastroenterol Hepatol. 2023;8(3):215–27